Mineral oil

Identification

Name
Mineral oil
Accession Number
DB11057
Type
Small Molecule
Groups
Approved, Vet approved
Description

Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced by solvent extraction, catalytic hydrotreating, or hydrocracking. Unrefined or mildly treated mineral oils are classified as Group 3 carcinogens by the World Health Organizations, as chronic exposure to these aromatics including alkylated polycyclic aromatic compounds (PAC) can lead to skin cancer.

Mineral oil is a common ingredient in baby lotions, cold creams, ointments and cosmetics to treat and prevent dry, rough, scaly, itchy skin and minor skin irritations. It is also used as a mild laxative for human or veterinary uses.

Synonyms
  • Food Grade Mineral Oil
  • Heavy Liquid Petrolatum
  • Heavy mineral oil
  • Liquid Paraffin
  • Liquid Petrolatum
  • Mineral Oil (high Viscosity)
  • Mineral Oil, Heavy
  • Paraffin Oil
  • Paraffin, Liquid
  • Paraffinum Liquidum
  • Petrolatum, Liquid
  • White Mineral Oil
External IDs
232-455-8 / E-905D / INS No.905D / INS-905D
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amoray Care BabyOil99.9 g/100mLTopicalMy Import Inc2015-03-262017-02-10Us
Bath Oil Liq 63.4%Liquid63.4 %TopicalBebia Pediatric, Division Of Stiefel Canada Inc.1991-12-311996-09-09Canada
Canadian National Pharma Group Inc Mineral Oil Heavy USPLiquid100 %OralCanadian National Pharma Group IncNot applicableNot applicableCanada
Clean It Zero RadianceCream63.2 mg/100mLTopicalF&Co Co., Ltd.2014-07-01Not applicableUs
CURAD Lubricant LaxativeEnema118 mL/118mLRectalMedline Industries2012-07-162015-01-01Us
Dynarex LaxativeLiquid99 g/100gOralDynarex Corporation2014-03-05Not applicableUs
EnemaEnema118 mL/118mLRectalH and P Industries, Inc. dba Triad Group1996-05-22Not applicableUs
EnemaEnema1 mL/1mLRectalDynarex Corporation2012-08-29Not applicableUs
EnemaEnema1 mL/1mLRectalAmerisource Bergen Drug Corportaion2004-02-132010-03-01Us
Enema mineral oilLiquid100 mL/100mLRectalMeijer Distribution1991-08-08Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
7 Select Hemorrhoidal Original StrengthMineral oil (140 mg/1g) + Petrolatum (749 mg/1g) + Phenylephrine hydrochloride (2.5 mg/1g)OintmentTopical7-ELEVEN, INC.2016-12-07Not applicableUs
Agarol Eml StrawberryMineral oil (1.6 ml) + Glycerin (200 mg) + Phenolphthalein (65 mg)EmulsionOralWarner Lambert Canada Inc.1992-12-311997-09-15Canada
Agarol PlainMineral oil (1.6 ml) + Glycerin (800 mg)EmulsionOralNumark Laboratories, Inc.1998-11-302016-06-02Canada
Agarol Plain EmlMineral oil (1.6 ml) + Glycerin (800 mg)EmulsionOralWarner Lambert Canada Inc.1992-12-311998-08-17Canada
Agarol Vanilla Laxative LiqMineral oil (1.6 ml) + Glycerin (200 mg) + Phenolphthalein (65 mg)LiquidOralWarner Lambert Canada Inc.1992-12-311997-09-15Canada
Alpha KeriMineral oil (91.7 %) + Lanolin (3 %)LiquidTopicalBristol Myers Squibb1958-12-311999-08-09Canada
Apj HemorrhoidalMineral oil (140 mg/1g) + Petrolatum (720 mg/1g) + Phenylephrine hydrochloride (2.55 mg/1g)OintmentTopicalA P J Laboratories Limited2013-07-01Not applicableUs
Artificial TearsMineral oil (150 mg/1g) + Petrolatum (830 mg/1g)OintmentOphthalmicAkorn1990-09-01Not applicableUs
Artificial TearsMineral oil (150 mg/1g) + Petrolatum (830 mg/1g)OintmentOphthalmicAkorn Animal Health, Inc.2015-06-152015-06-15Us
Artificial TearsMineral oil (150 mg/1g) + Petrolatum (830 mg/1g)OintmentOphthalmicRugby2011-10-07Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Camellia Cleansing BalmMineral oil (54.0999 g/100mL)SalveTopicalTov Co., Ltd2016-11-07Not applicableUs
Mizon Collagenic Aqua Volume Up Li P Essence RenewalMineral oil (7.26 g/10mL) + Octinoxate (0.40 g/10mL)LiquidTopicalMizon Co.,Ltd.2018-07-01Not applicableUs
Nature and Health Beauty (Moisturizing Cream, Whitening Cream)Mineral oil (1.2 g/120g) + Glycerin (1.2 g/120g)CreamTopicalNature And Health Beauty Co., Ltd.2015-04-16Not applicableUs
Nature and Health Beauty (Moisturizing Cream, Whitening Cream) (Mineral Oil and Glycerin)Mineral oil (1 g/100mL) + Glycerin (1 g/100mL)CreamTopicalNature And Health Beauty Co., Ltd.2016-03-23Not applicableUs
Nature and Health Beauty (Moisturizing Cream, Whitening Cream) (Mineral Oil and Glycerin)Mineral oil (1.2 g/120g) + Glycerin (1.2 g/120g)CreamTopicalNature And Health Beauty Co., Ltd.2016-03-13Not applicableUs
Pyung Gang Ato SoonMineral oil (0.45 g/45g)CreamTopicalPyung Gang Oriental Medical Clinic2015-04-02Not applicableUs
Pyung Gang Ato SoonMineral oil (0.45 g/45mL)CreamTopicalPyung Gang Oriental Medical Clinic2015-04-02Not applicableUs
Categories
UNII
T5L8T28FGP
CAS number
8042-47-5
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Mineral oil is not considered an active pharmacological ingredient in pharmaceutical preparations and so has no official indication. It is typically present in topical formulations as an emollient and occlusive agent [2].

Pharmacodynamics

Mineral oil blocks the loss of water from the skin allowing greater hydration of the epidermis [2].

Mechanism of action

Mineral oil sits on the surface of the skin and in spaces between cells and provides a hydrophobic barrier [2]. This barrier prevents trans-epidermal water loss to trap water in the skin. Overall this leads to greater hydration, flexibility, and softness of the stratum corneum.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(2-benzhydryloxyethyl)diethyl-methylammonium iodideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with (2-benzhydryloxyethyl)diethyl-methylammonium iodide.Experimental
1alpha-Hydroxyvitamin D5Mineral oil can cause a decrease in the absorption of 1alpha-Hydroxyvitamin D5 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Mineral oil.Approved, Vet Approved
AclidiniumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Aclidinium.Approved
AgmatineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Agmatine.Experimental, Investigational
AlfacalcidolMineral oil can cause a decrease in the absorption of Alfacalcidol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
AlfentanilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Alfentanil.Approved, Illicit
AlmasilateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Almasilate.Approved, Experimental
AloglutamolThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Aloglutamol.Approved
AlphacetylmethadolThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Alphaprodine.Illicit
Aluminium acetoacetateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Aluminium acetoacetate.Experimental
Aluminium glycinateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Aluminium glycinate.Experimental
Aluminum hydroxideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Aluminum hydroxide.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Mineral oil.Approved
AmiodaroneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Amiodarone.Approved, Investigational
AmitriptylineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Amitriptyline.Approved
AmlodipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Amlodipine.Approved
AmoxapineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Amoxapine.Approved
Anisotropine MethylbromideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Anisotropine Methylbromide.Approved
AranidipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Aranidipine.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Aripiprazole.Approved, Investigational
AtropineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Atropine.Approved, Vet Approved
AzelnidipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Azelnidipine.Approved, Investigational
AzosemideThe risk or severity of adverse effects can be increased when Azosemide is combined with Mineral oil.Investigational
BarnidipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Barnidipine.Approved
BecocalcidiolMineral oil can cause a decrease in the absorption of Becocalcidiol resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BenactyzineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Benactyzine.Withdrawn
BencyclaneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Bencyclane.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Mineral oil.Approved
BenidipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Benidipine.Approved, Investigational
BenzatropineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Benzatropine.Approved
BenziloneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Benzilone.Experimental
BenzquinamideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Benzquinamide.Withdrawn
BenzthiazideThe risk or severity of adverse effects can be increased when Benzthiazide is combined with Mineral oil.Approved
BepridilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Bepridil.Approved, Withdrawn
BevoniumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Bevonium.Experimental
BezitramideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Bezitramide.Experimental, Illicit, Withdrawn
BioallethrinThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Bioallethrin.Approved, Experimental
BiperidenThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Biperiden.Approved, Investigational
BornaprineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Bornaprine.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Brinzolamide is combined with Mineral oil.Approved
BromotheophyllineThe risk or severity of adverse effects can be increased when Bromotheophylline is combined with Mineral oil.Approved
BrompheniramineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Brompheniramine.Approved
BuclizineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Buclizine.Approved
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Mineral oil.Approved
BuprenorphineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Butylscopolamine.Approved, Investigational, Vet Approved
CalcidiolMineral oil can cause a decrease in the absorption of Calcidiol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
CalcipotriolMineral oil can cause a decrease in the absorption of Calcipotriol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CalcitriolMineral oil can cause a decrease in the absorption of Calcitriol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
Calcium CarbonateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium silicateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Calcium silicate.Experimental
CamylofinThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Camylofin.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Mineral oil.Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Canrenoic acid is combined with Mineral oil.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Canrenone is combined with Mineral oil.Investigational
CarboxyamidotriazoleThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Carboxyamidotriazole.Investigational
CarfentanilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Carfentanil.Illicit, Investigational, Vet Approved
CaroverineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Caroverine.Experimental
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Mineral oil.Approved, Vet Approved
ChlorphenoxamineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Chlorphenoxamine.Withdrawn
ChlorpromazineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Mineral oil.Approved
CholecalciferolMineral oil can cause a decrease in the absorption of Cholecalciferol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Cicletanine is combined with Mineral oil.Investigational
CilnidipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Cilnidipine.Approved, Investigational
CinnarizineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Cinnarizine.Approved, Investigational
ClevidipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Clevidipine.Approved, Investigational
ClidiniumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Clidinium.Approved
ClofenamideThe risk or severity of adverse effects can be increased when Clofenamide is combined with Mineral oil.Experimental
ClopamideThe risk or severity of adverse effects can be increased when Clopamide is combined with Mineral oil.Experimental
ClorexoloneThe risk or severity of adverse effects can be increased when Clorexolone is combined with Mineral oil.Experimental
ClozapineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Clozapine.Approved
CocaineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Codeine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Mineral oil.Approved, Investigational
CyclandelateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Cyclandelate.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Mineral oil.Approved
CyclopentolateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Cyclopentolate.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Cyclothiazide is combined with Mineral oil.Approved
CycrimineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Cycrimine.Approved
CyproheptadineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Cyproheptadine.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Mineral oil.Approved
DarifenacinThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Darifenacin.Approved, Investigational
DarodipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Darodipine.Experimental
DesipramineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Desipramine.Approved, Investigational
DexetimideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Dexetimide.Withdrawn
DexniguldipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Dexniguldipine.Experimental
DextromoramideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Dexverapamil.Experimental
DezocineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Dezocine.Approved, Investigational
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Mineral oil.Approved, Investigational
DicyclomineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Dicyclomine.Approved
DifemerineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Difemerine.Experimental
DihexyverineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Dihexyverine.Experimental
DihydrocodeineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Dihydromorphine.Experimental, Illicit
DihydrotachysterolMineral oil can cause a decrease in the absorption of Dihydrotachysterol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiltiazemThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Diltiazem.Approved, Investigational
DimetindeneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Dimetindene.Approved, Investigational
DiphemanilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Diphemanil.Experimental
Diphemanil MethylsulfateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Diphemanil Methylsulfate.Approved, Vet Approved, Withdrawn
DiphenhydramineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Diphenhydramine.Approved, Investigational
DiphenidolThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Diphenidol.Approved, Investigational, Withdrawn
DiphenoxylateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Diphenoxylate.Approved, Illicit
DisopyramideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Disopyramide.Approved
DorzolamideThe risk or severity of adverse effects can be increased when Dorzolamide is combined with Mineral oil.Approved
DosulepinThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Dosulepin.Approved
DotarizineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Dotarizine.Investigational
DoxepinThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Doxepin.Approved, Investigational
DoxercalciferolMineral oil can cause a decrease in the absorption of Doxercalciferol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxylamineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Doxylamine.Approved, Vet Approved
DPDPEThe therapeutic efficacy of Mineral oil can be decreased when used in combination with DPDPE.Experimental
DrospirenoneThe risk or severity of adverse effects can be increased when Drospirenone is combined with Mineral oil.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Mineral oil.Approved, Investigational
EldecalcitolMineral oil can cause a decrease in the absorption of Eldecalcitol resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
ElocalcitolMineral oil can cause a decrease in the absorption of Elocalcitol resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
EluxadolineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Eluxadoline.Approved, Investigational
EmeproniumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Emepronium.Experimental
EmopamilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Emopamil.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Mineral oil.Approved
EperisoneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Eperisone.Approved, Investigational
EpitizideThe risk or severity of adverse effects can be increased when Epitizide is combined with Mineral oil.Experimental
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Mineral oil.Approved
ErgocalciferolMineral oil can cause a decrease in the absorption of Ergocalciferol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Mineral oil.Approved, Investigational
EtanautineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Etanautine.Experimental
EthopropazineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Ethosuximide.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Mineral oil.Withdrawn
EthylmorphineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Ethylmorphine.Approved, Illicit
EtorphineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Etorphine.Illicit, Vet Approved
EtybenzatropineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Etybenzatropine.Experimental
FelodipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Felodipine.Approved, Investigational
FendilineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Fendiline.Withdrawn
FenpiveriniumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Fenpiverinium.Experimental
FenquizoneThe risk or severity of adverse effects can be increased when Fenquizone is combined with Mineral oil.Experimental
FentanylThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Fesoterodine.Approved
Fish oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Fish oil.Approved, Nutraceutical
FlavoxateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Flavoxate.Approved
FlunarizineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Flunarizine.Approved
FluoxetineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Fluoxetine.Approved, Vet Approved
FlupentixolThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Flupentixol.Approved, Investigational, Withdrawn
FluspirileneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Fluspirilene.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Mineral oil.Approved, Vet Approved
GabapentinThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Gabapentin.Approved, Investigational
Gallamine TriethiodideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Gallamine Triethiodide.Approved
GallopamilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Gallopamil.Investigational
GlycopyrroniumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Heroin.Approved, Illicit, Investigational
HexocycliumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Hexocyclium.Approved
HomatropineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Homatropine.Approved
Homatropine MethylbromideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Homatropine Methylbromide.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Mineral oil.Approved, Vet Approved
HydrocodoneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Hydrocodone.Approved, Illicit, Investigational
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Mineral oil.Approved, Investigational
HydromorphoneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Hydromorphone.Approved, Illicit
HydrotalciteThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Hydrotalcite.Approved, Experimental, Investigational
HyoscyamineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Hyoscyamine.Approved
IbopamineThe risk or severity of adverse effects can be increased when Ibopamine is combined with Mineral oil.Experimental
ImidafenacinThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Imidafenacin.Approved, Investigational
ImipramineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Mineral oil.Approved
InecalcitolMineral oil can cause a decrease in the absorption of Inecalcitol resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
IpratropiumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Ipratropium.Approved
IsofluraneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Isoflurane.Approved, Vet Approved
IsopropamideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Isopropamide.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Isosorbide is combined with Mineral oil.Approved, Investigational
IsradipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Isradipine.Approved, Investigational
KetobemidoneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Ketobemidone.Approved, Investigational
LacidipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Lacidipine.Approved, Investigational
LamotrigineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Lamotrigine.Approved, Investigational
LercanidipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Lercanidipine.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Levetiracetam.Approved, Investigational
Levomethadyl acetateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Levorphanol.Approved
LidoflazineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Lidoflazine.Experimental
LofentanilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Lofentanil.Illicit
LomerizineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Lomerizine.Experimental
LoperamideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Loperamide.Approved
MagaldrateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Magaldrate.Approved, Withdrawn
Magnesium sulfateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Mineral oil.Approved, Investigational
MaprotilineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Maprotiline.Approved, Investigational
MaxacalcitolMineral oil can cause a decrease in the absorption of Maxacalcitol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MazaticolThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Mazaticol.Experimental
MebeverineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Mebeverine.Approved, Investigational
MebutizideThe risk or severity of adverse effects can be increased when Mebutizide is combined with Mineral oil.Experimental
MefrusideThe risk or severity of adverse effects can be increased when Mefruside is combined with Mineral oil.Experimental
MentholThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Menthol.Approved
MepenzolateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Mepenzolate.Approved
MeptazinolThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Meptazinol.Experimental
MersalylThe risk or severity of adverse effects can be increased when Mersalyl is combined with Mineral oil.Approved
MethadoneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Methadone.Approved
Methadyl acetateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Methadyl Acetate.Approved, Illicit
MethanthelineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Methantheline.Approved, Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Mineral oil.Approved
MethotrimeprazineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
MethscopolamineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Methscopolamine.Approved
MethsuximideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mineral oil.Approved
Methylscopolamine bromideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Methylscopolamine bromide.Approved
MeticraneThe risk or severity of adverse effects can be increased when Meticrane is combined with Mineral oil.Experimental
MetixeneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Metixene.Approved
MetocurineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Metocurine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Mineral oil.Approved
MibefradilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Mibefradil.Investigational, Withdrawn
MivacuriumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Mivacurium.Approved
MorphineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Morphine.Approved, Investigational
MuzolimineThe risk or severity of adverse effects can be increased when Muzolimine is combined with Mineral oil.Experimental
NaftopidilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Naftopidil.Investigational
NalbuphineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Nalbuphine.Approved
NaltrexoneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NicardipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Nicardipine.Approved, Investigational
NicomorphineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Nicomorphine.Experimental
NifedipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Nifedipine.Approved
NiguldipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Niguldipine.Experimental
NiludipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Niludipine.Experimental
NilvadipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Nimodipine.Approved, Investigational
NisoldipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Nisoldipine.Approved
NitrendipineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Nitrendipine.Approved, Investigational
NormethadoneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Normethadone.Approved, Illicit
NortriptylineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Nortriptyline.Approved
NylidrinThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Nylidrin.Approved
OlanzapineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Olanzapine.Approved, Investigational
OpiumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Opium.Approved, Illicit
OrphenadrineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Orphenadrine.Approved
OtiloniumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Otilonium.Experimental, Investigational
OxitropiumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Oxitropium.Investigational
OxybutyninThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Oxybutynin.Approved, Investigational
OxycodoneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Oxymorphone.Approved, Investigational, Vet Approved
OxyphencyclimineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Oxyphencyclimine.Approved
OxyphenoniumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Oxyphenonium.Approved
PancuroniumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Pancuronium.Approved
ParicalcitolMineral oil can cause a decrease in the absorption of Paricalcitol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ParoxetineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Paroxetine.Approved, Investigational
PenfluridolThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Penfluridol.Experimental
PentazocineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Pentazocine.Approved, Vet Approved
PenthienateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Penthienate.Experimental
PethidineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Pethidine.Approved
PhenazocineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Phenazocine.Experimental
PhenglutarimideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Phenglutarimide.Experimental
PhenoperidineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Phenoperidine.Experimental
PhylloquinoneThe serum concentration of Phylloquinone can be decreased when it is combined with Mineral oil.Approved, Investigational
PinaveriumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Pinaverium.Approved
PipecuroniumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Pipecuronium.Approved
PipenzolateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Pipenzolate.Experimental
PiperidolateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Piperidolate.Experimental
PirenzepineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Pirenzepine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Mineral oil.Approved
PiritramideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Piritramide.Approved, Investigational
PizotifenThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Pizotifen.Approved
PoldineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Poldine.Experimental
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Mineral oil.Approved
PotassiumThe risk or severity of adverse effects can be increased when Potassium is combined with Mineral oil.Approved, Experimental
Potassium cationThe risk or severity of adverse effects can be increased when Potassium cation is combined with Mineral oil.Approved, Investigational
Potassium CitrateThe risk or severity of adverse effects can be increased when Potassium Citrate is combined with Mineral oil.Approved, Investigational, Vet Approved
PrenylamineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Prenylamine.Withdrawn
PrifiniumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Prifinium.Experimental
ProcyclidineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Procyclidine.Approved
PromazineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Promazine.Approved, Vet Approved
PromethazineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Promethazine.Approved, Investigational
PropanthelineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Propantheline.Approved
PropiomazineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Propiomazine.Approved
PropiverineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Propiverine.Approved, Investigational
QuetiapineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Mineral oil.Approved
QuinidineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Quinidine.Approved, Investigational
RapacuroniumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Rapacuronium.Approved, Withdrawn
RemifentanilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Remifentanil.Approved
RevefenacinThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Revefenacin.Investigational
RociverineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Rociverine.Experimental
RocuroniumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Rocuronium.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Rolofylline is combined with Mineral oil.Investigational
ScopolamineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Scopolamine.Approved, Investigational
SeletracetamThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Seletracetam.Investigational
SeocalcitolMineral oil can cause a decrease in the absorption of Seocalcitol resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium tartrateThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Sodium tartrate.Approved
SolifenacinThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Solifenacin.Approved
SpiradolineThe risk or severity of adverse effects can be increased when Spiradoline is combined with Mineral oil.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Mineral oil.Approved
SufentanilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Sufentanil.Approved, Investigational
TacalcitolMineral oil can cause a decrease in the absorption of Tacalcitol resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
TapentadolThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Tapentadol.Approved
Tartaric acidThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Tartaric acid.Approved
TerodilineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Terodiline.Experimental
TetrahydropalmatineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Tetrahydropalmatine.Investigational
TetrandrineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Tetrandrine.Experimental
TheobromineThe risk or severity of adverse effects can be increased when Theobromine is combined with Mineral oil.Approved, Investigational
ThonzylamineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Thonzylamine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Ticrynafen is combined with Mineral oil.Withdrawn
Tiemonium iodideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Tiemonium iodide.Experimental
TilidineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Tilidine.Experimental
TimepidiumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Timepidium.Experimental
TiotropiumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Tiotropium.Approved
Tolfenamic AcidThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolterodineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Tolterodine.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Tolvaptan is combined with Mineral oil.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Mineral oil.Approved
TramadolThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Tramadol.Approved, Investigational
TranilastThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Tranilast.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Mineral oil.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Mineral oil.Approved, Vet Approved
TridihexethylThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Tridihexethyl.Withdrawn
TriflupromazineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Trihexyphenidyl.Approved
TrimebutineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Trimebutine.Approved
TrimethadioneThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Trimethadione.Approved
TropatepineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Tropatepine.Experimental
TropicamideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Tropicamide.Approved, Investigational
TrospiumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Trospium.Approved
UlaritideThe risk or severity of adverse effects can be increased when Ularitide is combined with Mineral oil.Investigational
UmeclidiniumThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Umeclidinium.Approved
VerapamilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Verapamil.Approved
VinpocetineThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Vinpocetine.Investigational
Vitamin DMineral oil can cause a decrease in the absorption of Vitamin D resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical, Vet Approved
WIN 55212-2The therapeutic efficacy of Mineral oil can be decreased when used in combination with WIN 55212-2.Experimental
XipamideThe risk or severity of adverse effects can be increased when Xipamide is combined with Mineral oil.Experimental
ZiconotideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Ziconotide.Approved
ZonisamideThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Zonisamide.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Mackerer CR, Griffis LC, Grabowski Jr JS, Reitman FA: Petroleum mineral oil refining and evaluation of cancer hazard. Appl Occup Environ Hyg. 2003 Nov;18(11):890-901. [PubMed:14555442]
  2. Kleiman N (2018). Dry Skin. In Compendium of Therapeutic Choices for Minor Ailments (2nd ed.). Canadian Pharmacists Association.
External Links
PubChem Substance
347911096
Wikipedia
Mineral_oil
ATC Codes
A06AA51 — Liquid paraffin, combinationsA06AA01 — Liquid paraffin
AHFS Codes
  • 84:24.12 — Basic Ointments and Protectants
  • 56:12.00 — Cathartics and Laxatives
MSDS
Download (48 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentUlcerative Colitis (UC)1
2CompletedTreatmentConjunctivitis, Seasonal Allergic1
2, 3CompletedTreatmentAbstinence Syndrome / Behavior, Addictive1
3CompletedTreatmentConjunctivitis, Viral1
3CompletedTreatmentEye Dryness1
3RecruitingPreventionBenign Gynecologic Neoplasm1
3Unknown StatusTreatmentAdenovirus / Conjunctivitis1
4CompletedBasic ScienceInflammatory Reaction1
4CompletedDiagnosticColonoscopy1
4CompletedTreatmentColorectal Cleansing Prior Operation1
4CompletedTreatmentConjunctivitis, Seasonal Allergic2
4Not Yet RecruitingOtherAdverse Drug Events / Cataracts / Mydriasis1
4Unknown StatusDiagnosticEye Dryness1
4WithdrawnTreatmentDry Eye Syndrome (DES)1
Not AvailableCompletedPreventionEye Dryness1
Not AvailableCompletedScreeningColorectal Cancers1
Not AvailableCompletedTreatmentDry Eye Syndrome (DES)1
Not AvailableCompletedTreatmentEye Dryness1
Not AvailableCompletedTreatmentIntraocular Pressure1
Not AvailableCompletedTreatmentMigraines1
Not AvailableCompletedTreatmentUnilateral Retinoblastoma1
Not AvailableRecruitingTreatmentAdenoviral Conjunctivitis / Conjunctivitis1
Not AvailableTerminatedTreatmentOccasional Constipation1
Not AvailableUnknown StatusDiagnosticHirschsprung's Disease1
Not AvailableUnknown StatusTreatmentPain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
OilTopical99.9 g/100mL
LiquidTopical63.4 %
SalveTopical54.0999 g/100mL
CreamTopical63.2 mg/100mL
LiquidOral99 g/100g
EnemaRectal1 mL/1mL
EnemaRectal118 mL/118mL
LiquidRectal100 mL/100mL
OintmentTopical52.74 %
LotionTopical18 %
OintmentRectal; Topical
EnemaRectal100 %
OintmentTopical100 %
GelTopical
LiquidOral
LotionTopical100 %
OintmentTopical
LiquidOral; Topical
LiquidOral1000 mg/1mL
LiquidTopical1000 mg/1mL
OintmentOphthalmic
LiquidTopical8 g/100mL
LiquidOral2.5 mL/5mL
GelOral78 %
LiquidOral
LiquidTopical
EmulsionOral
EnemaRectal113.115 g/118mL
EnemaRectal118 g/118mL
LiquidOral
LiquidOral100 %
LiquidOral99.9 mg/1mL
LiquidOral999 mg/1mL
LiquidOral; Topical999 mg/1mL
OilOral100 mg/100mL
OilOral471.9528 g/472mL
OilOral; Topical100 mg/100mL
OilOral; Topical15 mg/15mg
OilOral; Topical15 mg/15mL
OilOral; Topical15 mL/15mL
OilRectal100 g/100g
LiquidTopical100 %
OilTopical471.99 g/472mL
LiquidOral30 ml
SolutionOral99.9 %
OilTopical327.54 g/410mL
OilOral1 mg/1mL
OilTopical99.9 mL/100mL
OilOral999 mg/1mL
CreamTopical0.45 g/45mL
CreamTopical0.45 g/45g
Kit
EmulsionOphthalmic
LiquidTopical75 mg/150mL
CreamTopical
CreamTopical49.46 g/90mL
OilTopical100 mL/100mL
OilTopical1 mL/1mL
Solution / dropsOphthalmic
GelOphthalmic
LiquidTopical
LotionTopical
OintmentRectal
OilTopical100 g/200mL
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
boiling point (°C)310MSDS
water solubilityInsolubleMSDS
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on December 03, 2015 09:51 / Updated on September 17, 2018 21:03